Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Stress alters the expression of cancer-related genes in the prostate

  • Ivan E. Flores1,
  • Jorge A. Sierra-Fonseca1,
  • Olinamyr Davalos1,
  • Luis A. Saenz1,
  • Maria M. Castellanos1,
  • Jaidee K. Zavala1 and
  • Kristin L. Gosselink1Email author
Contributed equally
BMC Cancer201717:621

https://doi.org/10.1186/s12885-017-3635-4

Received: 1 August 2016

Accepted: 28 August 2017

Published: 5 September 2017

Abstract

Background

Prostate cancer is a major contributor to mortality worldwide, and significant efforts are being undertaken to decipher specific cellular and molecular pathways underlying the disease. Chronic stress is known to suppress reproductive function and promote tumor progression in several cancer models, but our understanding of the mechanisms through which stress contributes to cancer development and progression is incomplete. We therefore examined the relationship between stress, modulation of the gonadotropin-releasing hormone (GnRH) system, and changes in the expression of cancer-related genes in the rat prostate.

Methods

Adult male rats were acutely or repeatedly exposed to restraint stress, and compared to unstressed controls and groups that were allowed 14 days of recovery from the stress. Prostate tissue was collected and frozen for gene expression analyses by PCR array before the rats were transcardially perfused; and brain tissues harvested and immunohistochemically stained for Fos to determine neuronal activation.

Results

Acute stress elevated Fos expression in the paraventricular nucleus of the hypothalamus (PVH), an effect that habituated with repeated stress exposure. Data from the PCR arrays showed that repeated stress significantly increases the transcript levels of several genes associated with cellular proliferation, including proto-oncogenes. Data from another array platform showed that both acute and repeated stress can induce significant changes in metastatic gene expression. The functional diversity of genes with altered expression, which includes transcription factors, growth factor receptors, apoptotic genes, and extracellular matrix components, suggests that stress is able to induce aberrant changes in pathways that are deregulated in prostate cancer.

Conclusions

Our findings further support the notion that stress can affect cancer outcomes, perhaps by interfering with neuroendocrine mechanisms involved in the control of reproduction.

Keywords

StressProstate cancerHPG axisProstate gene expression

Background

Stress is a highly complex process that disrupts homeostasis and involves environmental and psychosocial factors acting as stimuli (stressors) to induce a series of responses by the peripheral and central nervous systems [1]. One of the physiological systems that becomes activated during stress is the hypothalamic-pituitary-adrenal (HPA) axis. Activation of the HPA axis triggers the release of corticotrophin-releasing hormone (CRH) from the paraventricular nucleus of the hypothalamus (PVH) which, in turn, induces the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), ultimately resulting in the production of cortisol by the adrenal cortex. The entire axis is then regulated via negative feedback provided by cortisol at the hypothalamic and pituitary levels [2]. Chronic stress can adversely alter hormone levels, thus affecting the regulation of the stress response which can ultimately have a negative effect on the overall physiology of the body [3, 4]. Therefore, stress can have deleterious effects on health, contributing to the incidence and progression of diseases such as cancer.

Chronic stress is, in fact, believed to be a significant factor in the development and progression of cancer, and a growing body of evidence suggests that the neuroendocrine stress response machinery is an important mediator during tumorigenesis and metastasis [59]. Impaired T cell-mediated immunity, enhanced tumor proliferation, and decreased survival have been shown in response to chronic stress in a mouse lymphoma model [10]. Suppression of T cell function by chronic stress is also known to increase susceptibility to skin cancer [11], and β-adrenergic signaling has been shown to be linked to tumor growth and invasion in pancreatic and ovarian cancers [12, 13]. Stress-related hormones have been shown to be involved in accelerating cell proliferation and tumor growth in breast and prostate cancer [14, 15], while inhibiting cell growth in other tumors such as neuroblastoma [16], thus indicating that cell type and specific hormones are critical factors in mediating the stress-cancer relationship.

In addition to altering the regulation of the HPA axis, acute and chronic stress can also affect the hypothalamic-pituitary-gonadal (HPG) axis, which can in turn disrupt reproductive function since the hormones within this axis are responsible for orchestrating mammalian reproduction. The first step of the HPG axis is the secretion of gonadotropin-releasing hormone (GnRH) by the preoptic area of the hypothalamus, which then stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary in a fashion that is dependent on the frequency and amplitude of GnRH pulses; the gonadotropic hormones LH and FSH then regulate steroidogenesis and gametogenesis in the gonads [17, 18]. Stress can suppress the HPG axis through inhibiting GnRH secretion which, in turn, suppresses pituitary release of LH and FSH [19, 20]. Chronic restraint stress in rats also reduces GnRH pulsatility and lowers plasma LH and FSH [21]. It should be noted, however, that rebound GnRH secretion can occur following earlier suppression of its release [2224]. GnRH is strongly implicated as having a role cancer, but conflicting data on the effects of GnRH on cellular function have been published. GnRH analogs inhibit growth and proliferation in reproductive cancer cell lines in vitro [21, 2528], and also decrease growth in melanoma cells [29], suggesting that GnRH may have broad anti-cancer functions. Furthermore, GnRH receptor agonists are currently being evaluated for potential use in the treatment of prostate, breast, endometrial and ovarian cancers as well as glioblastomas and melanomas, due to their ability to halt cellular proliferation [30]. However, GnRH receptor antagonists may alternatively be used to knock down the effects of endogenous GnRH and inhibit the release of steroids that stimulate tumor growth in certain cancers [31], demonstrating that GnRH does not always produce desired effects. While accumulating evidence seems to support a clear link between stress and cancer, a direct, mechanistic relationship through which stress can alter reproductive function and subsequently contribute to cancer has not been established.

Prostate cancer (PC) is the most commonly diagnosed non-skin malignancy and the second most prevalent cause of cancer death in the U.S., accounting for ~10% of newly diagnosed male cancer cases worldwide [3234]. Taking current screening habits into consideration, it is predicted that 1 in 6 men alive today in the U.S. will be diagnosed with the disease, and roughly 3% of those patients will die from it [35, 36]. GnRH analogs have been previously used as antineoplastic drugs against PC [3739]. The use of GnRH agonists is the current choice for androgen-deprivation therapy for advanced and metastatic PC. The rationale behind this treatment is to stimulate the release of LH to achieve feedback regulation of testosterone levels. This method initially leads to a testosterone surge that can worsen the disease, but continuous administration of the agonist eventually downregulates the pituitary GnRH-R, regulating LH release and decreasing testosterone production [40]. On the other hand, GnRH antagonists act by directly binding to GnRH-R, thus avoiding the testosterone “flare” caused by GnRH agonists [41, 42]. Even though it is clear that chronic stress leads to the suppression of GnRH, and GnRH constitutes a target for PC treatment, no study to date has directly examined the relationship between stress-induced modulation of the GnRH system and PC-related outcomes in a single in vivo model. Therefore, we aimed to determine if chronic stress modulates hypothalamic GnRH and consequently affects the expression of genes associated with prostate cell proliferation, and if recovery from stress could induce a rebound of GnRH release that subsequently contributes to an upregulation of genes that promote metastasis.

Methods

Experimental animals

Adult male Sprague/Dawley Rats were housed individually in standard cages and maintained on a 12:12 h cycle with food and water ad libitum. Rats were allowed to acclimate for one week before being used for experiments. All animals used in this study were cared for in accordance with the Guide for the Care and Use of Laboratory Animals, and all procedures were approved by the UTEP Institutional Animal Care and Use Committee (IACUC protocol A-201006-1).

Restraint stress

Rats were randomly assigned to 7 groups (n = 5/group): Control (Con), Acute restraint (Acu), Repeated restraint (Rep), Control plus recovery (Con + Rec), Acute restraint plus recovery (Acu + Rec), Repeated restraint plus recovery (Rep + Rec). A final group underwent repeated restraint and recovery followed by an additional acute restraint exposure (R + A). Physical restraint was used as an emotional stressor, with the rats placed inside an acrylic restraining device (Kent Scientific) for 30 min. All restraint and exposure was done near the beginning of the light cycle, between 0900 and 1100 h. Acu rats were exposed to open restraining devices in their home cages for 30 min/d for 20 consecutive days, and then restrained for 30 min on the 21st day only, while Rep rats were restrained for 30 min on each of the 21 days. Con rats were exposed to the restraining device daily for 30 min but never restrained. Rats in the recovery groups were handled identically to their Con, Acu or Rep counterparts, but then allowed 14d of recovery with no manipulation after their stress exposure. Rats in the final group (R + A) were restrained for 30 min/d for 21d, free from stress exposure for 13d, and finally restrained for 30 min on the last day.

Perfusion and tissue collection

At the end of the restraining treatments, the animals were deeply anesthetized with 100 mg/kg of sodium pentobarbital, i.p. (Nembutal®; McKesson), followed by perfusion through the ascending aorta with ~100 mL of 0.9% saline, and 400–500 mL of 4% paraformaldehyde (JT Baker) at pH 9.5 in 0.1 M borate buffer. Brains were dissected, post-fixed for 5 h at 4 °C, and cryoprotected overnight at 4 °C in KPBS with 10% sucrose, then serially sectioned in 30 μm sections on a freezing microtome (Model SM 2000R; Leica) and stored in antifreeze (30% ethylene glycol, 20% glycerol) at −20 °C until used for immunohistochemical analysis. Prostate tissues were dissected during the saline and tissue samples (ranging from 15 to 30 mg) were obtained, placed on dry ice, and stored at −80 °C until use for transcriptional analysis.

Immunohistochemistry and cell counting

Brain sections were immunohistochemically stained for Fos and GnRH as an indicator of neuronal activation in response to stress. Fos was localized using a nickel-intensified avidin-biotin-immunoperoxidase technique. Tissue sections were incubated overnight at 4 °C in primary antiserum against Fos (1:10,000; Oncogene Science), and incubated on the following day for 1 h at room temperature in secondary antibody (biotinylated goat anti-rabbit IgG, 1:200; Vector). An avidin-biotin-complexing solution (Vectastain Elite kit; Vector) was applied for 1 h, and a nickel-enhanced glucose oxidase method using diaminobenzidine (DAB) as a chromogen was used to visualize specific binding. Separate series of brain sections were immunostained for GnRH using a similar method but without the nickel enhancement (primary antiserum used at 1:10,000; Abcam). Stained sections were mounted on gelatin-coated slides, dehydrated through a graded series of ethanol and xylene, and coverslipped with DPX mountant (Electron Microscopy Sciences). The number of Fos-positive cells in the PVH was quantified by simple cell counting on a light microscope coupled to a digital imaging system (Zeiss). Counts were taken unilaterally from 4 sections throughout the rostrocaudal extent of the PVH, and summed for each animal. Group averages were then calculated, and compared statistically using two-tailed t-tests with a p value of ≤0.05 considered significant.

Transcriptional analysis

Total RNA was isolated from prostate tissue samples (15–30 mg) using a commercially available kit (RNeasy mini kit, Qiagen) according to manufacturer’s instructions. RNA concentration and purity were determined using a Nanodrop spectrophotometer and samples were stored at −20 °C until use. cDNA was generated using a RT2 first strand kit and used in two different targeted PCR arrays (SABiosciences): one array for genes associated with cancer pathways (Cancer Pathway Finder PARN-033A) and another one for genes associated with tumor metastasis (Tumor Metastasis PARN-028A). For the cancer pathway array, an n of 5 was evaluated for all groups except Con + Rec (n = 4) and R + A (n = 2); in the metastasis array an n of 3 per group was used except for Con + Rec (n = 2). Gene expression changes were analyzed by means of the ΔCt (cycle threshold) method [43], subtracting the average Ct values obtained from the housekeeping genes provided in the array from the average Ct values of every gene of interest present in the arrays. Only Ct values below 35 were used in the study, as determined by the quality control reactions included in the array. Statistical analysis on the ΔCt experimental values was performed using Microsoft Excel and Sigma Plot 12.5 software, with a statistical significance of p ≤ 0.05 determined by two-tailed t-test for between group comparisons. Further testing employed one-way ANOVA with Bonferroni correction to account for multiple comparisons and to determine overall effects.

Molecular function and biological process of genes with altered expression

In order to identify the cellular and molecular functions of the genes with significant changes in expression, the UniProtKB Knowledgebase [44] was used. Gene IDs from the arrays (as provided by the manufacturer, SABiosciences) were entered into the UniProtKB search engine, and only search results from rat were consulted. The information from GO-molecular function and GO-biological process was used to identify the function of the genes and the biological processes in which they participate. Preference was given to those results that were derived from experimental evidence, as indicated by the database.

Results

Effects of restraint stress on hypothalamic neuroendocrine pathways

Brain tissue sections containing the PVH were immunohistochemically stained for Fos as a marker of neuronal activation following restraint stress and recovery. The number of Fos-expressing cells increased significantly following acute stress when compared to control (Fig. 1). This effect habituated with repeated stress exposure, as counts of Fos-positive neurons in the PVH in repeatedly stressed rats (Rep) were not different from those seen in Con rats. The 14-day recovery period post-stress ameliorated the Fos response in Acu rats, such that the number of Fos-positive neurons returned control levels.
Fig. 1

Stress-induced expression of Fos in the PVH. Representative photomicrographs are provided for PVH sections from each treatment group immunohistochemically stained for Fos. The bar graph displays quantitative results of the total number of Fos-positive cells in Control (Con), Acutely stressed (Acu), Repeatedly Stressed (Rep), Control plus Recovery (Con + Rec) Acute plus Recovery (Acu + Rec), Repeated plus Recovery (Rep + Rec), and Repeated plus Recovery plus Acute (R + A) animals. Bars are Mean ± SEM. n = 3 for each group, except Rep where n = 4. Symbols: *, significantly different (p < 0.05) from Con; †, significantly different (p < 0.05) from Acu

Separate sections of tissue were stained for Fos and GnRH, and singly- and doubly-labeled cells quantified in the medial preoptic area. We were able to identify small numbers of neurons that expressed GnRH and were activated by stress (Fos-positive), but no statistically significant differences were found by treatment group (data not shown).

Acute and repeated restraint stress upregulate cancer pathway-associated genes in the rat prostate

Transcriptional analysis of prostate tissue from rats subjected to Acu restraint stress revealed a group of seven genes in the cancer pathway platform that displayed significantly upregulated expression (Table 1). This same set of genes remained significantly elevated in their expression following Rep stress, with the exception of one gene (Arnt, Aryl hydrocarbon receptor nuclear translocator, a transcription factor) which returned to control-like levels in the Rep group. A recovery period (no restraint) of 14 days post-Rep stress was sufficient to return the expression of these genes to normal (control) levels. Within this group of genes, Ets2 (V-ets erythroblastosis virus E26 oncogene homolog 2) and Skp2 (S-phase kinase-associated protein 2, p45) were identified as proto-oncogenes, and Krt14 (Keratin 14) is a structural protein that is widely used as a marker for prostate adenocarcinoma.
Table 1

Cancer pathway genes with significant upregulation after Acu and Rep stress, returning to normal after recovery

Gene ID/ Accesion

Gene name

Fold change

Con vs Acu

Fold change

Con vs Rep

Molecular function/biological process

Arnt P41739

Aryl hydrocarbon receptor nuclear translocator

1.51

1.23 (ns)

Transcription factor/response to hypoxia

Ets2 D4AAH4

V-ets erythroblastosis virus E26 oncogene homolog 2 (avian)

1.83

1.93

Transcription factor/cell differentiation

Krt14 Q6IFV1

Keratin 14

2.27

2.27

Cytoskeleton/maintenance of cell morphology

Serpinb2 P29524

Serpin peptidase inhibitor, clade B (ovalbumin), member 2

1.97

1.99

Endopeptidase inhibitor/apoptosis

Skp2 B2GUZ0

S-phase kinase-associated protein 2 (p45)

1.56

1.67

Ubiquitin ligase/cell cycle regulation

Slc2a1 P11167

Solute carrier family 2 (facilitated glucose transporter, member 1

1.25

1.32

Glucose transporter/metabolism (nutrient uptake)

Tinf2 Q5XIB8

TERF 1 (TRF1)- interacting nuclear factor 2

4.29

6.11

Telomeric DNA binding/chrosomome stability

Italicized text denotes a gene that was only upregulated with Acu (but not Rep) stress, as indicated by “ns”; bold text denotes genes identified as proto-oncogenes. Accession numbers and molecular function/biological process obtained from UniProtKB database

A different set of 25 genes were upregulated after Rep stress, but did not show significant changes when subjected to Acu stress (Table 2), suggesting that transient stress exposure is not sufficient to change their expression levels. These genes varied in function from cell cycle regulation, to metabolism, to DNA repair and cell adhesion. Importantly, 2 of these genes, Fms-related tyrosine kinase 1 (Flt1) and Mitogen activated protein kinase kinase 1 (Map2k1), were both identified as proto-oncogenes involved in mitogenic cell signaling. Also worth noting was the finding that about one third of these genes participate in apoptosis. Expression levels and statistical evaluation of genes in the Cancer Pathway platform are included as Additional files (Additional files 1 and 2).
Table 2

Cancer pathway genes significantly upregulated after Rep stress (but not after Acu)

Gene ID/ Accession

Gene name

Fold change

Con vs Rep

Molecular function/biological process

Acly P16638

ATP citrate lyase

2.14

Lyase enzyme/metabolism (bioenergetics)

Angpt1 O35460

Angiopoietin 1

1.91

Vascular growth factor/angiogenesis

Apaf1 Q9EPV5

Apoptotic peptidase activating factor 1

1.42

Endopeptidase/apoptosis

Atp5a1 P15999

ATP synthase, H+ transpoting, mitochondrial F1 complex, alpha subunit

1.84

ATP synthesis/metabolism (bioenergetics)

Casp2 P55215

Caspase 2

2.10

Endopeptidase/apoptosis

Casp7 O88550

Caspase 7

1.87

Endopeptidase/apoptosis

Casp9 Q920G4

Caspase 9, apoptosis-related cysteine peptidase

1.96

Endopeptidase/apoptosis

Ccnd3 P48961

Cyclin D3

1.54

Kinase/cell cycle regulation

Cdc20 Q62623

Cell division cycle 20 homolog (S. cerevisiae)

1.92

Regulatory protein/cell cycle regulation

Cdh2 Q9Z1Y3

Cadherin 2

3.07

Cell adhesion

Cflar C0H5Y5

CASP8 and FADD-like apoptosis regulator

2.08

Endopeptidase/apoptosis

Cpt2 P18886

Carnitine palmitoyltransferase 2

2.06

Lipid transferase/metabolism (fatty acid)

Dkc1 P40615

Dyskeratosis congenita 1, dyskerin

1.66

rRNA processing/proliferation

E2f4 D4A9V4

E2F transcription factor 4

2.10

Transcription factor/proliferation

Ercc5 D3ZTV2

Excision repair cross-complementing rodent repair deficiency, Complementation group 5

1.85

Endonuclease/DNA excision repair

Flt1 P53767

Fms-related tyrosine kinase 1

2.77

Growth factor receptor/proliferation, migration

Foxc2 Q63246

Forkhead box C2

1.91

Transcription factor/proliferation, differentiation

G6pd P05370

Glucose −6-phosphate dehydrogenase

2.38

Dehydrogenease/metabolism (carbohydrates)

Igfbp7 Q5RJM3

Insulin-like growth factor binding protein 7

1.89

Growth factor binding/response to hormones

Map2k1 Q01986

Mitogen activated protein kinase kinase 1

1.83

Mitogenic protein kinase/proliferation

Nol3 Q62881

Nucleolar protein 3 (apoptosis repressor with CARD domain)

2.11

Regulatory protein/apoptosis

Pgf Q63434

Placental growth factor

1.60

Growth factor/proliferation, differentiation

Pp1r15a Q6IN02

Ppp1r15a

Protein phosphatase 1, regulatory (inhibitor) subunit 15A

1.91

Phosphatase/apoptosis

Sod1 P07632

Superoxide dismutase 1, soluble

1.96

Dismutase enzyme/oxidative stress

Wee1 Q63802

Wee 1 homolog (S. pombe)

1.29

Kinase/cell cycle regulation

Bold text denotes proto-oncogenes. Accession numbers and molecular function/biological process obtained from UniProtKB database

Restraint stress differentially affects the expression of prostate genes affiliated with the metastatic program

Acu stress significantly upregulated the expression of only three genes known to be involved in tumor metastasis (Table 3), which were fibroblast growth factor receptor 4, heparanase, and integrin beta 3. The expression of these genes was not increased under Rep stress conditions, however, and their expression levels returned to control values when allowed to recover from Acu stress, suggesting that the observed upregulation induced by Acu stress could be a transient effect, as seen previously with Arnt (Table 1).
Table 3

Metastasis-associated genes with significant upregulation after Acu stress (but not Rep), returning to normal after recovery

Gene ID/ Accession

Gene name

Fold change

Con vs Acu

Molecular function/ biological process

Fgfr4 Q498D6

Fibroblast growth factor receptor 4

3.32

Growth factor receptor/ proliferation

Hpse Q71RP1

Heparanase

2.75

Endoglycosidase/ cell adhesion

Itgb3 Q8R2H2

Integrin, beta 3

2.45

Receptor protein/ cell adhesion, angiogenesis

Accession numbers and molecular function/biological process obtained from UniProtKB database

Rep stress was able to induce the significant upregulation of several genes in the metastasis array (Table 4), one of which (Src) is a very well-established proto-oncogene that participates in promoting cell proliferation. Although the expression levels of the majority of these genes decreased when the rats were allowed to recover from Rep stress, the expression of two genes (Chemokine (C-C motif) ligand 7 and Plasminogen activator, urokinase receptor) did not fully return to control levels, indicating a persistent effect of Rep stress. In addition to increasing the expression of the genes mentioned above, Rep stress significantly downregulated the expression of p53, a very well characterized tumor suppressor gene. Importantly, the expression of p53 remained significantly downregulated (although not to the extent observed after Rep stress) even when allowed to recover from stress. Complete datasets containing expression levels and statistical evaluation of genes in the Metastasis platform are included as Additional files (Additional files 3 and 4).
Table 4

Metastasis-associated genes that displayed significant changes in expression after Rep stress (but not Acu)

Gene ID/ Accession

Gene name

Fold change

Con vs Rep

Molecular function/biological process

Ccl7 Q9QXY8

Chemokine (C-C motif) ligand 7

11.00

Cytokine/immune function (chemotaxis)

Il1b Q63264

Interleukin 1 beta

3.84

Cytokine/immune function (inflammation)

Plaur P49616

Plasminogen activator, urokinase receptor

6.63

Transmembrane protein/differentiation

Src Q9WUD9

V-src sarcoma

1.93

Non-receptor tyrosine kinase/proliferation

Tp53* P10361

Tumor protein p53

0.50

Transcription factor/DNA repair, apoptosis

Italicized text denotes genes that remained significantly changed after recovery. Only one gene was found to have downregulated expression (asterisk); bold text denotes genes identified as proto-oncogenes; bold and italicized text denotes tumor suppressor genes. Accession numbers and molecular function/biological process obtained from UniProtKB database

Discussion

Accumulating evidence provided by epidemiological studies strongly suggests that chronic psychological stress plays an important role in the initiation and progression of cancer [4547]. Results from clinical studies also strongly support a link between stressful events in a patient’s life with reduced cancer survival [46, 48]. However, the precise mechanisms by which chronic stress influences tumorigenesis and carcinogenesis remain poorly understood. Although much progress has been made through the use of animal models, most of these studies have used mouse xenograft and genetic models to study the effects of chronic stress (such as restraint and social isolation) on cancer progression and metastasis [12, 4952].To the best of our knowledge, this is the first study designed to identify changes in the expression of cancer-associated genes as a response to chronic emotional stress in a specific organ of an otherwise healthy animal. This allowed us to determine changes in prostate gene expression in response to chronic stress compared to basal levels, which has provided us with insights as to which cellular pathways can be initially disrupted by stress that may lead to abnormal cell proliferation and tumor formation.

Our results demonstrate that restraint stress (both acute and chronic) is sufficient to alter the expression of genes associated with tumor proliferation and metastasis in the rat prostate. Previous studies using a rat model of chronic stress (by restraint water immersion) have shown that 14 days of stress can induce histological changes in the prostate, as well as proliferation of epithelial cells of the ventral lobe of the prostate [53, 54]. Although the expression of proliferation-associated genes was not measured in these studies, our data supports the notion that restraint stress can induce aberrant gene expression, which could potentially lead to increased cell proliferation. The genes included in this investigation have broad cellular functions and their up and downregulation may not necessarily indicate cancer development or progression in this model. However the sensitivity of these genes to stress provides evidence of potential mechanisms through which increased stress exposure might ultimately contribute to cancer.

Although PC is usually considered a disease of aged men (~70% of diagnosed patients are over 65), and age itself is one of the major risk factors in developing the disease [36], histopathological studies using prostate tissue samples from younger healthy patients (age 20–40) have demonstrated the presence of proliferative lesions, indicating that cancer initiation may take place at an early age and remain undetected for many years [5558]. Our data demonstrate aberrant expression of cancer-related genes in the tissues of adult animals in response to chronic stress. It is therefore reasonable to speculate that chronic stress may either trigger localized cell proliferation at an early age, which can then accumulate additional “hits” over time until progressing into full fledged cancer. Another interesting possibility is that chronic stress may serve to aggravate pre-existing neoplastic lesions, thus contributing to cancer progression.

Despite the lack of knowledge regarding specific mechanisms underlying tumorigenic processes induced by stress, previous studies have identified several physiological and molecular pathways that are influenced by stress and can contribute to cancer progression. Several studies have focused on immune function, since it is very well established that stress can downregulate immune function, which in turn can impair the immune response against tumor cells [5961]. Importantly, it was recently shown that chronic stress can induce a re-organization of lymphatic vessels to facilitate the dissemination of tumor cells in a mouse model of breast cancer, and this was proven to be regulated by the sympathetic nervous system [62]. However, decreased immune function alone cannot account for the multitude of processes that need to be altered in order for cancer to progress. One major contributor is the neuroendocrine response to stress, including the HPA and HPG axes, which trigger hormone signaling descending from the brain and the pituitary to the adrenal glands and reproductive tissues. These systems can have myriad effects on peripheral tissues, including neurotransmitter release and production of mitogenic factors that can promote tumor growth by acting directly on receptors present in cancer cells [6], as well as suppression of hormone pulses that can potentially promote cell proliferation, such as GnRH.

In the case of our study, the cell counts of activated neurons in the PVH, as identified by Fos immunostaining, provide evidence that acute restraint stress is activating the HPA axis. This response is well-established, and involves an increase in the neuroendocrine secretion of corticotropin-releasing factor and, ultimately, enhanced release of the glucocorticoid hormone cortisol. Of our genes displaying upregulated expression levels in the Acu condition, a number of them are regulated by cortisol or have related functions. Krt14, for example, is one of many glucocorticoid-regulated keratin genes that tend to be repressed in skin following cortisol-receptor monomers binding to glucocorticoid response elements in the presence of corticosteroid binding protein [63]. Our observed increase in Krt14 expression may be tissue-specific or a function of alternate binding strategies. Increases in Arnt and Fgfr4 may directly result from increased cortisol exposure. The aryl hydrocarbon receptor and glucocorticoid receptor have been shown previously to interact and participate in complex developmental and physiological processes [64]. Cortisol has been shown to increase Fgfr4 expression, and this molecule has been specifically associated with extracellular matrix degradation and tumor invasion in prostate and other cancers [65]. Metabolically, the glucoregulatory capacity of cortisol provides another link to Fgfr4 which also functions in glucose regulation [65], and to Slc2a1, a facilitated glucose transporter that showed upregulated expression after acute stress in our study. Lastly, prostate cancer patients have been shown to have increased circulating levels of cortisol [66], suggesting a possible bi-directional relationship between this stress hormone and cancer. Future experiments will focus on identifying the effects of our stress paradigm on different players within the HPG axis.

The broad molecular functions and biological processes affected by the genes that displayed significantly altered expression levels in our study underlie the observation that stress can affect a multitude of cellular functions that can ultimately lead to increased cell proliferation, including apoptosis, mitogenic signaling, extracellular matrix, DNA repair, and altered bioenergetics. This is not surprising, as cancer is a highly complex, multistep process that requires cells to acquire specific traits in order to proliferate and evolve into a malignant phenotype, and though it is unlikely that stress alone can provide cells with such specific characteristics, it is certainly possible that, given the progressive nature of cancer, stress can facilitate deregulation of certain pro- and anti-proliferative cellular processes [6, 67]. Interestingly, our results showed that restraint stress upregulated the expression of genes involved in the activation of apoptotic pathways (i.e. caspases 2, 7, and 9) and are thus associated with anti-proliferative activity. Recent studies have suggested that psychological stress can promote prostate carcinogenesis in mouse xenograft models via inhibition of apoptosis [68, 69]. While this finding appears to conflict with our gene expression data, it is also possible that our observed increase in the expression of pro-apoptotic genes could be a compensatory response by the prostate cells since we also observed an upregulation of genes that promote cell proliferation (i.e. cyclin D3, Src, MAPK). In fact, prostate tissue is known to be very sensitive to signals that influence tumorigenic growth, and therefore maintains a cell death/proliferation equilibrium [70, 71].

Of noteworthy importance is the upregulated expression of several genes identified as proto-oncogenes, including genes with very well characterized roles in cancer progression such as Map2k1 and Src. Importantly, the expression of tumor protein p53, one of the most characterized tumor suppressor genes, was found to be downregulated in accordance with its cellular role in cancer where inactivation of this gene is sufficient to predispose individuals to cancer [72, 73]. Moreover, chronic stress has been found to promote tumorigenesis in a p53 genetic mouse model of cancer, with tumor formation depending on glucocorticoid action [52].

Conclusions

The results of the present study illustrate the effects of emotional stress on prostate tissue gene expression. As shown by the functions and processes in which the affected genes participate, stress can influence a wide variety of cellular functions, and may be an early stimulus that promotes prostate cancer incidence or progression through modification by endocrine mediators. That recovery from stress is able to restore the expression of some genes, but not others, to normal levels provides support for future investigations into the importance of stress timing and duration in cancer diagnoses.

Abbreviations

ACTH: 

adrenocorticotropic hormone

CRH: 

corticotrophin-releasing hormone

CT: 

cycle threshold

DAB: 

diaminobenzidine

FSH: 

follicle-stimulating hormone

GnRH: 

gonadotropin-releasing hormone

GnRH-R: 

gonadotropin-releasing hormone receptor

HPA: 

hypothalamic-pituitary-adrenal

HPG: 

hypothalamic-pituitary-gonadal

LH: 

luteinizing hormone

PC: 

prostate cancer

PVH: 

paraventricular nucleus of the hypothalamus

Declarations

Acknowledgements

We would like to acknowledge the support provided by Ana Betancourt and the Genomic Analysis Core Facility of the NIH-funded Border Biomedical Research Center at UTEP. We also wish to express our gratitude to the UTEP Laboratory Animal Resource Center staff for their support of the vivarium work.

Funding

This work was supported by grant U54 RR022762-03S1 (RTRN), grant G12 MD007592 (NIH), and grant 52,005,908 (HHMI). The funding bodies had no role in the design of the study, the collection, analysis or interpretation of data, or in writing the manuscript.

Availability of data and materials

The datasets supporting the conclusions of the present study are included as within the manuscript and as supplementary files. No sequence data were generated in the performance of this study.

Authors’ contributions

IEF, JASF, OD, LAS, MMC, and JKZ contributed to data acquisition, analysis, and interpretation; KLG and JKZ conceived and designed the study; IEF, JASF, and KLG wrote the manuscript. All authors read, revised and approved the final manuscript.

Ethics approval

The animals used in this study were cared for in accordance with the Guide for the Care and Use of Laboratory Animals, and all procedures were approved by the UTEP Institutional Animal Care and Use Committee (IACUC protocol A-201006-1).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso

References

  1. Chrousos G. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374–81.View ArticlePubMedGoogle Scholar
  2. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87:873–04.View ArticlePubMedGoogle Scholar
  3. Vanitallie TB. Stress: a risk factor for serious illness. Metabolism. 2002;51:40–5.View ArticlePubMedGoogle Scholar
  4. Glaser R, Kiecolt-Glaser JR. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5:243–51.View ArticlePubMedGoogle Scholar
  5. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol. 2010;6:1863–81.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Yuan A, Wang S, Li Z, Huang C. Psychological aspect of cancer: from stressor to cancer progression. Exp Ther Med. 2010;1:13–8.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Lutgendorf S, Sood A. Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med. 2011;73:724–30.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Payne JK. State of the science: stress, inflammation, and cancer. Oncol Nurs Forum. 2013;41:533–40.View ArticleGoogle Scholar
  9. Powell ND, Tarr AJ, Sheridan JF. Psychosocial stress and inflammation in cancer. Brain Behav Immun. 2013;30:S41–7.View ArticlePubMedGoogle Scholar
  10. Frick LR, Arcos ML, Rapanelli M, Zappia MP, Brocco M, Mongini C, Genaro AM, Cremaschi GA. Chronic restraint stress impairs T-cell immunity and promotes tumor progression in mice. Stress. 2009;12:134–43.View ArticlePubMedGoogle Scholar
  11. Saul AN, Oberyszyn TM, Daugherty C, Kusewitt D, Jones S, Jewell S, Malarkey WB, Lehman A, Lemeshow S, Dhabhar FS. Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst. 2005;97:1760–7.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939–44.View ArticlePubMedGoogle Scholar
  13. Kim-Fuchs C, Le CP, Pimentel MA, Shackleford D, Ferrari D, Angst E, Hollande F, Sloan EK. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun. 2014;40:40–7.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Badino GR, Novelli A, Girardi C, Di Carlo F. Evidence for functional β-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res. 1996;33:255–60.View ArticlePubMedGoogle Scholar
  15. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000;6:703–6.View ArticlePubMedGoogle Scholar
  16. Pifl C, Zezula J, Spittler A, Kattinger A, Reither H, Caron MG, Hornykiewicz O. Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J. 2001;15:1607–9.PubMedGoogle Scholar
  17. Weinbauer GF, Nieschlag E. Gonadotropin control of testicular germ cell development. Adv Exp Med Biol. 1993;377:55–65.View ArticleGoogle Scholar
  18. Smith JT, Clark IJ. Gonadotropin inhibitory hormone function in mammals. Trends Endocrinol Metab. 2010;21:255–60.View ArticlePubMedGoogle Scholar
  19. Rivier C, Rivest S. Effect of stress on the activity of the hypothalamic-pituitary-gonadal axis: peripheral and central mechanisms. Biol Reprod. 1991;45:523–32.View ArticlePubMedGoogle Scholar
  20. Kirby ED, Geraghty AC, Ubuka T, Bentley GE, Kaufer D. Stress increases putative gonadotropin inhibitory hormone and decreases luteinizing hormone in male rats. Proc Natl Acad Sci. 2009;106:11324–9.View ArticlePubMedPubMed CentralGoogle Scholar
  21. López-Calderón A, Gonzaléz-Quijano MI, Tresguerres JA, Ariznavarreta C. Role of LHRH in the gonadotrophin response to restraint stress in intact male rats. J Endocrinol. 1990;124:241–6.View ArticlePubMedGoogle Scholar
  22. Kolho KL, Huhtaniemi I. Suppression and recovery of pituitary gonadotrophin secretion in intact and orchidectomized rats treated neonatally with a gonadotrophin-releasing hormone antagonist. J Endocrinol. 1989;122:519–26.View ArticlePubMedGoogle Scholar
  23. Elias AN, Iyer K, Pandian MR, Weathersbee P, Stone PS, Tobis J. Beta-endorphin/beta-lipotropin release and gonadotropin secretion after acute exercise in normal males. J Appl Physiol. 1986;61:2045–9.PubMedGoogle Scholar
  24. Gianotti L, Veldhuis JD, Destefanis S, Lanfranco F, Ramunni J, Arvat E, Marzetto M, Boutignon F, Deghenghi R, Ghigo E. Suppression and recovery of LH secretion by a potent and selective GnRH-receptor antagonist peptide in healthy early follicular-phase women are mediated via selective control of LH secretory burst mass. Clin Endocrinol. 2003;59:526–32.View ArticleGoogle Scholar
  25. Hapgood JP, Sadie H, van Biljon W, Ronacher K. Regulation of expression of mammalian gonadotrophin-releasing hormone receptor genes. J Neuroendocrinol. 2005;17:619–38.View ArticlePubMedGoogle Scholar
  26. Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison D, Langdon S, Millar RP. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res. 2008;68:6331–40.View ArticlePubMedGoogle Scholar
  27. Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P, Type I. Gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab. 2009;94:1761–7.View ArticlePubMedGoogle Scholar
  28. HM W, Wang HS, Huang HY, Soong YK, MacCalman CD, Leung PC. GnRH signaling in intrauterine tissues. Reproduction. 2009;137:769–77.View ArticleGoogle Scholar
  29. Moretti RM, Montagnani Marelli M, Mai S, Limonta P. Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of alpha3 integrin and MMP-2 expression and activity. Int J Oncol. 2008;33:405–13.PubMedGoogle Scholar
  30. Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33:784–811.View ArticlePubMedGoogle Scholar
  31. Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther. 2007;320:1113–8.View ArticlePubMedGoogle Scholar
  32. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.View ArticlePubMedGoogle Scholar
  33. Chang ET, Boffetta P, Adami HO, Cole P, Mandel JSA. Critical review of the epidemiology of agent Orange/TCDD and prostate cancer. Eur J Epidemiol. 2014;29:667–723.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Tao ZQ, Shi AM, Wang KX, Zhang WD. 2015. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015;19:805–12.PubMedGoogle Scholar
  35. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA J Cancer Clin. 2011;61:212–36.View ArticleGoogle Scholar
  36. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30:195–200.View ArticlePubMedGoogle Scholar
  37. Redding TW, Schally AV. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci. 1981;78:6509–12.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci. 1982;79:1658–62.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol. 2005;206:205–13.View ArticlePubMedGoogle Scholar
  40. Debruyne FM. Gonadotropin-releasing hormone antagonist in the management of prostate cancer. Rev Urol. 2004;6:S25–32.PubMedPubMed CentralGoogle Scholar
  41. Persson BE. Kold OlesenT, Jensen JK. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology. 2009;90:235–44.View ArticlePubMedGoogle Scholar
  42. Kimura T, Sasaki H, Akazawa K, Egawa S. Gonadotropin-releasing hormone antagonist: a real advantage? Urol Oncol. 2015;33:322–8.View ArticlePubMedGoogle Scholar
  43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.View ArticlePubMedGoogle Scholar
  44. UniProt (Universal Protein Resource). www.uniprot.org. Last accessed 30 May 2016.
  45. Garssen B. Psychological factors and cancer development: evidence after 30 years of research. Clin. Psychol Rev. 2004;24:315–38.Google Scholar
  46. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5:466–75.View ArticlePubMedGoogle Scholar
  47. Denaro N, Tomasello L, Russi EG. Cancer and stress: what’s matter? From epidemiology: the psychologist and oncologist point of view. J Cancer Ther Res. 2014;3:1–11.View ArticleGoogle Scholar
  48. Andersen BL, Yang HC, Farrar WB, Golden-Kreutz DM, Emery CF, Thornton LM, Young DC, Carson WE 3rd. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 2008;113:3450–3458.Google Scholar
  49. Mazur-Kolecka B, Machala O, Skowron-Cendrzak A, Kubera M, Bubak-Satora M, Basta-Kaim A, Roman A. Effect of immobilization stress on tumor growth in mice. Neoplasma. 1994;41:183–6.PubMedGoogle Scholar
  50. Villano Bonamin L, Barbuto JA, Malucelli BE. Effects of social isolation on ehrlich tumor growth and tumor leukocyte infiltration in mice: evidence of participation of the submaxillary salivary gland. Neuroimmunomodulation. 2001;9:313–8.View ArticlePubMedGoogle Scholar
  51. Hasegawa H, Saiki I. Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res. 2002;93:729–35.View ArticlePubMedGoogle Scholar
  52. Feng Z, Liu L, Zhang C, Zheng T, Wang J, Lin M, Zhao Y, Wang X, Levine AJ, Chronic HW. Restraint stress attenuates p53 function and promotes tumorigenesis. Proc Natl Acad Sci. 2012;109:7013–8.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Huang S, Fang X, Meng Y, Chen Y, Zhang X, Zhao S. Sympathetic nervous system overactivity in the Wistar rat with proliferative lesions of ventral prostate induced by chronic stress. Urol Int. 2009;83:230–5.View ArticlePubMedGoogle Scholar
  54. Huang S, Zhang X, Xu L, Li Q, Zhao Q. Expression of nerve growth factor in the prostate of male rats in response to chronic stress and sympathetic denervation. Exp Ther Med. 2014;8:1237–40.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Yatani R, Kusano I, Shiraishi T, Hayashi T, Stemmermann GN. Latent prostatic carcinoma: pathological and epidemiological aspects. Jpn J Clin Oncol. 1989;19:319–26.PubMedGoogle Scholar
  56. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8:439–43.PubMedGoogle Scholar
  57. Shiraishi T, Watanabe M, Matsuura H, Kusano I, Yatani R, Stemmermann GN. The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo. 1994;8:445–7.PubMedGoogle Scholar
  58. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24:1967–2000.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Glaser R, MacCallum RC, Laskowski BF, Malarkey WB, Sheridan JF, Kiecolt-Glaser JK. Evidence for a shift in the Th-1 to Th-2 cytokine response associated with chronic stress and aging. J Gerontol A Biol Sci Med Sci. 2001;56:M477–82.View ArticlePubMedGoogle Scholar
  60. Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun. 2003;17:321–8.View ArticlePubMedGoogle Scholar
  61. Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005;23:7105–13.View ArticlePubMedGoogle Scholar
  62. Le CP, Nowell CJ, Kim-Fuchs C, Botteri E, Hiller JG, Ismail H, Pimentel MA, Chai MG, Karnezis T, Rotmensz N, Renne G, Gandini S, Pouton CW, Ferrari D, Möller A, Stacker SA, Sloan EK. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun. 2016;7:10634.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Radoja N, Komine M, Jho SH, Blumenberg M, Tomic-Canic M. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol. 2000;20:4328–39.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Sato S, Shirakawa H, Tomita S, Tohkin M, Gonzalez FJ, Komai M. The aryl hydrocarbon receptor and glucocorticoid receptor interact to activate human metallothionein 2A. Toxicol Appl Pharmacol. 2013;273:90–9.View ArticlePubMedGoogle Scholar
  65. Brito LP, Lerario AM, Bronstein MD, Soares IC, Mendonca BB, Fragoso MCBV. Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing’s disease outcome. J Clin Endocrinol Metab. 2010;95:E271–9.View ArticlePubMedGoogle Scholar
  66. Fabre B, Grosman H, Gonzalez D, Machulsky NF, Repetto EM, Mesch V, Lopez MA, Mazza O, Berg G. Prostate cancer, high cortisol levels and complex hormonal interaction. Asian Pac J Cancer Prev. 2016;17:3167–71.PubMedGoogle Scholar
  67. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle. 2007;6:430–3.View ArticlePubMedGoogle Scholar
  68. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R Jr, Danial N, Datta SR, Kulik G. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest 2013;123:874–886.Google Scholar
  69. Sun X, Bao J, Nelson KC, Li KC, Kulik G, Zhou X. Systems modeling of anti-apoptotic pathways in prostate cancer: psychological stress triggers a synergism pattern switch in drug combination therapy. PLoS Comput Biol. 2013;9:e1003358.View ArticlePubMedPubMed CentralGoogle Scholar
  70. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res. 1995;1:473–80.PubMedPubMed CentralGoogle Scholar
  71. Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer. 1996;69:357–63.View ArticlePubMedGoogle Scholar
  72. Malkin D. Li Fraumeni syndrome. Genes Cancer. 2011;2:475–84.View ArticlePubMedPubMed CentralGoogle Scholar
  73. Garcia PB, Attardi LD. Illuminating p53 function in cancer with genetically engineered mouse models. Semin Cell Dev Biol. 2014;27:74–85.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement